OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Discovery is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Artificial intelligence in drug discovery: recent advances and future perspectives	134
Challenges identifying efficacious miRNA therapeutics for cancer	113
Open access in silico tools to predict the ADMET profiling of drug candidates	102
What is the current value of MM/PBSA and MM/GBSA methods in drug discovery?	98
The importance of sulfur-containing motifs in drug design and discovery	66
Artificial intelligence, machine learning, and drug repurposing in cancer	66
Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs	55
How do we address neglected sulfur pharmacophores in drug discovery?	49
An up-to-date overview of computational polypharmacology in modern drug discovery	45
Automated patch clamp in drug discovery: major breakthroughs and innovation in the last decade	44
Knowledge graphs and their applications in drug discovery	41
An overview of rational design of mRNA-based therapeutics and vaccines	40
Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders	39
Artificial intelligence in early drug discovery enabling precision medicine	39
Discovery of CFTR modulators for the treatment of cystic fibrosis	38
Strategies for targeting undruggable targets	37
How necessary are animal models for modern drug discovery?	36
Assigning confidence to molecular property prediction	35
Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery	33
Electrophilic warheads in covalent drug discovery: an overview	33
An update on the importance of plasma protein binding in drug discovery and development	33
Current models of pulmonary fibrosis for future drug discovery efforts	32
Frontiers of metal-coordinating drug design	30
The application of machine learning techniques to innovative antibacterial discovery and development	30
Critical assessment of AI in drug discovery	29

The latest automated docking technologies for novel drug discovery	28
Glycyrrhetinic acid: a promising scaffold for the discovery of anticancer agents	28
The combination of artificial intelligence and systems biology for intelligent vaccine design	28
Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?	27
Novel therapeutic strategies for treatingPseudomonas aeruginosainfection	27
An update on dengue vaccine development, challenges, and future perspectives	26
Evolution of the drug-target residence time model	26
Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis	26
Animal models of Chagas disease and their translational value to drug development	26
Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?	25
An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives	24
The 1,2,3-triazole ‘all-in-one’ ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool	24
Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently?	24
Multi-objective optimization methods in novel drug design	24
Success stories of AI in drug discovery - where do things stand?	24
An overview of ProTide technology and its implications to drug discovery	23
Future prospects for Antimicrobial peptide development: peptidomimetics and antimicrobial combinations	23
The design and discovery of phospholipase A₂ inhibitors for the treatment of inflammatory diseases	23
Approaches for the discovery of new cell-penetrating peptides	22
Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery	22
In vivo near-infrared fluorescent optical imaging for CNS drug discovery	22
Drug development for noise-induced hearing loss	21
Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions	20
What place does molecular topology have in today’s drug discovery?	20
Advances in the discovery of novel agents for the treatment of glaucoma	20
Nucleic acid therapeutics: a focus on the development of aptamers	20
The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?	19
The preclinical discovery and development of agomelatine for the treatment of depression	19
1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design	19
Advances in biocatalytic and chemoenzymatic synthesis of nucleoside analogues	18
Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics	18
Advances in mRNA-based drug discovery in cancer immunotherapy	18
Drug discovery strategies for modulating oxidative stress in gastrointestinal disorders	18
The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease	18
Computational approaches for the design of modulators targeting protein-protein interactions	17
Can drug repurposing strategies be the solution to the COVID-19 crisis?	17
Approaches to mitigate the risk of serious adverse reactions in covalent drug design	17
Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery	17
Disentangling the fibrous microenvironment: designer culture models for improved drug discovery	17
Is PROTAC technology really a game changer for central nervous system drug discovery?	17
Using 3D in vitro cell culture models in anti-cancer drug discovery	16
Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy	16
The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19	16
Antimicrobial peptides: a promising strategy for lung cancer drug discovery?	16
The machine learning life cycle and the cloud: implications for drug discovery	16
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)	16
Terpyridines as promising antitumor agents: an overview of their discovery and development	16
What makes a good fragment in fragment-based drug discovery?	16
The design and discovery of topoisomerase I inhibitors as anticancer therapies	16
Boswellic acids: privileged structures to develop lead compounds for anticancer drug discovery	15

Phenotypic screening techniques forCryptosporidiumdrug discovery	15
Evolution of assay interference concepts in drug discovery	15
An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases	15
Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade	15
Recent advances in quantitative structure–activity relationship models of antimalarial drugs	15
How can we improve peptide drug discovery? Learning from the past	15
Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer	15
Recent in vivo advances of spirocyclic scaffolds for drug discovery	15
Advances in venom peptide drug discovery: where are we at and where are we heading?	15
Peptide-based targeting of connexins and pannexins for therapeutic purposes	15
The discovery and development of IP3 receptor modulators: an update	14
What are the challenges with multi-targeted drug design for complex diseases?	14
The challenges of generalizability in artificial intelligence for ADME/Tox endpoint and activity prediction	14
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future	14
Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere?	14
Modeling percutaneous absorption for successful drug discovery and development	14
Targeting the GLI family of transcription factors for the development of anti-cancer drugs	14
The recent application of 3D-QSAR and docking studies to novel HIV-protease inhibitor drug discovery	14
Challenges with matrix metalloproteinase inhibition and future drug discovery avenues	14
Approaches for targeting the mycobactin biosynthesis pathway for novel anti-tubercular drug discovery: where we stand	14
Reinforcement learning for systems pharmacology-oriented and personalized drug design	13
Hidden allosteric sites and De-Novo drug design	13
The preclinical discovery and development of rectal artesunate for the treatment of malaria in young children: a review of the evidence	12
What are the current challenges for machine learning in drug discovery and repurposing?	12
Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection	12
The emerging potential of interactive virtual reality in drug discovery	12
Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies	12
Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	12
Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges	11
High-throughput screening in multicellular spheroids for target discovery in the tumor microenvironment	11
Phage display technology for target determination of small-molecule therapeutics: an update	11
Using deep neural networks to explore chemical space	11
Targeting Autophagy In Disease: Recent Advances In Drug Discovery	11